All In Biotech

Drug Trial Radar · NCT06056297

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Jun 6, 2024

Primary completion

Sep 2027

Study completion Nov 2027

Sponsor

Lead sponsor
X4 PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.

Conditions

  • Neutropenia

Interventions

  • MavorixaforDrug

    Mavorixafor will be administered per schedule specified in the arm description.

  • PlaceboDrug

    Placebo will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-primary Endpoint: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment PeriodTime frame: Up to 52 Weeks
  2. Co-primary Endpoint: Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) ResponseTime frame: Up to 52 weeks

Locations

115 sites in 25 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • UC Irvine

    Irvine, California · Recruiting

  • Orso Health

    La Jolla, California · Recruiting

  • University of California, Los Angeles-UCLA

    Los Angeles, California · Recruiting

  • Orso Health

    Torrance, California · Withdrawn

  • GNP Research

    Cooper City, Florida · Recruiting

  • University of Southern Florida

    St. Petersburg, Florida · Recruiting

  • Children's Healthcare of Atlanta (CHOA)

    Atlanta, Georgia · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Boston Children's Cancer Center

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • St. Jude Childrens; Research Hospital

    Memphis, Tennessee · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Cook Children's Medical Center

    Fort Worth, Texas · Recruiting

  • Texas Children's Hospital/ Baylor College of Medicine

    Houston, Texas · Recruiting

  • Sarah Cannon Research Institute

    Woodland, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Froedtert And Medical College Of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Hospital El Cruce

    Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clínicas Córdoba

    Córdoba, Argentina · Recruiting

  • Santorio 9 de Julio

    San Miguel de Tucumán, Argentina · Recruiting

  • Perth Children's Hospital

    Nedlands, Australia · Recruiting

  • Icon Cancer Centre Southport

    Southport, Australia · Recruiting

  • Ballarat Oncology And Haematology Services

    Wendouree, Australia · Recruiting

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium · Recruiting

  • University of Alberta Hospital

    Edmonton, Canada · Recruiting

  • BC Children's Hospital

    Vancouver, Canada · Recruiting

  • Clinica IMBANACO S.A.S

    Cali, Colombia · Recruiting

  • Clínica del Country

    Chapinero, Colombia · Recruiting

  • Hospital Pablo Tobón Uribe

    Medellín, Colombia · Recruiting

  • Fundacion Cardiovascular de Colombia-Instituto del Corazon Florida Blanca

    Floridablanca, Santander Department, Colombia · Recruiting

  • The University Hospital Brno

    Brno, Czechia · Withdrawn

  • Motol University Hospital

    Prague, Czechia · Withdrawn

  • Institute of Hematology and Pediatric Oncology - Lyon

    Lyon, France · Recruiting

  • Hôpital Saint Louis

    Paris, France · Recruiting

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.